Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma.
18 Years
N/A
Both
Carcinoma, Carcinoma Renal Cell, Kidney Neoplasms, Kidney Diseases, Chemokines
Trial Information
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma.
Based on a physiopathological rationale, the use of RCC-directed antiangiogenic therapies
into clinical practice leads to conclusive results and makes RCC a particularly well-suited
tumor type to study factors involved in the angiogenic process. Furthermore the intensive
use of targeted therapies in clinical practice raised new questions about their management.
Therefore the identification of new molecular biomarkers is important:
- to improve the precision of prognostic models currently based on clinical, biological
or histopathological variables
- to identify high risk patients that could benefit from an adjuvant treatment or a
closer postoperative follow-up
- to predict the response to antiangiogenic therapies and therefore identify the drug
which is likely to be the most effective within an ever increasing pharmacopeia
- to follow the therapy as precisely as possible, predict or attest the disease
progression justifying a therapeutic modification
Low CXCL4, CXCL4L1 and CXCR3 tumor expression levels are associated with bad prognosis
factors in RCC. Consequently their interest in RCC is worth being evaluated, in two
subgroups : Localized / locally advanced renal cell carcinoma and Metastatic renal cell
carcinoma.
Inclusion Criteria:
- Patients diagnosed with localized, locally advanced or metastatic Renal Cell
Carcinoma :
- having a radical or partial nephrectomy
- or treated by RCC-directed targeted therapy
- Patients who have signed and dated an informed consent form with the investigator
Exclusion Criteria:
- under 18 years old
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3)
Outcome Description:
Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3) will be evaluated by the association of these markers with time to event occurrence. Localized or locally advanced renal cell carcinoma group: local recurrence contralateral recurrence extra-renal distant recurrence (metastatic progression) specific cancer death nonspecific cancer death Metastatic renal cell carcinoma group : local recurrence for patients who underwent a nephrectomy contralateral reccurence metastatic progression specific cancer death nonspecific cancer death
Outcome Time Frame:
3 years
Safety Issue:
No
Principal Investigator
Jean-Christophe BERNHARD, Dr
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Hospital Bordeaux, France
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
CHUBX 2010/45
NCT ID:
NCT01339975
Start Date:
June 2011
Completion Date:
June 2019
Related Keywords:
- Carcinoma
- Carcinoma Renal Cell
- Kidney Neoplasms
- Kidney Diseases
- Chemokines
- Renal Cell Carcinoma
- Nephrectomy
- Antiangiogenics
- Chemokines
- Prognostic value
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
- Kidney Diseases
- Neoplasms, Glandular and Epithelial
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Adjuvants, Immunologic
- Physiological Effects of Drugs
- Pharmacologic Actions
- Biomarkers
- Targeted therapies
- Surgery
- Neoplasms
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Diseases
- Kidney Neoplasms
Name | Location |
|---|
